Flubromazolam has been marketed online as a designer drug and is a benzodiazepine analog closely linked to triazolam and flubromazepam. Flubromazolam is known to be highly potent, and concerns have been posed that, in particular, clonazolam and flubromazolam may pose a comparatively higher risk than other designer benzodiazepines because of their potential to trigger extreme oral sedation and amnesia at doses as low as 0.5 mg. At doses of just 3 mg of flubromazolam, life-threatening adverse reactions have been observed.